Here's Fierce on all the latest Brunello clinical trial news I missed whilst away:
. . .Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug that the Big Pharma bought in a $3 billion takeover.
The phase 2b/3 trial compared Merck's remigromig to ranibizumab, the VEGF inhibitor that Roche’s Genentech sells as Lucentis in the U.S. Mimicking a natural ligand called norrin, remigromig agonizes the Wnt signaling pathway. The pathway supports the restoration and maintenance of blood-retinal barrier integrity, suggesting remigromig could improve visual outcomes. . . .
Remigromig was well tolerated, Merck said. However, the company reported higher rates of proliferative diabetic retinopathy, vitreous hemorrhage and treatment discontinuations because of adverse events on remigromig than on ranibizumab. Merck is running further analyses to characterize the findings. Eyebiotech, remigromig’s original developer, saw no drug-related adverse events in a phase 1b/2a trial.
Merck will present data from the trial at the American Academy of Ophthalmology Annual Meeting next month. . . .
Merck acquired remigromig and the Tie2xVEGF bispecific, MK-8748, in its $1.3 billion upfront takeover of EyeBio in 2024. Merck is also on the hook for up to $1.7 billion in milestones. The assets are part of Merck’s efforts to grow beyond the loss of exclusivity for Keytruda. . . .
Now you know. Seriously jet-lagging -- but smiling just the same. Will see the lil' grand-nieces this evening for a Sunday night barbeque dinner. Grin.
नमस्ते
No comments:
Post a Comment